Chemomab Therapeutics to Present at 2024 Investor Conferences

TEL AVIV, Israel, Aug. 28, 2024 -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Dr. Adi Mor, will be presenting at two upcoming events. These events are the H.C. Wainwright 26th Annual Global Investment Conference and the HBM Biopharma Summit 2024 in Zurich, Switzerland.

Dr. Mor's presentation at the H.C. Wainwright conference will be prerecorded and available via webcast starting September 9, 2024, at 7:00 am ET. The presentation will remain accessible for 90 days. The HBM Biopharma Summit presentation, on the other hand, will be conducted live and is scheduled for 10:45 am CET on September 23, 2024, at the Park Hyatt Zurich. Unlike the Wainwright presentation, the HBM Summit presentation will not be webcast.

Chemomab Therapeutics is focused on developing innovative treatments for fibro-inflammatory diseases, which currently have high unmet medical needs. Central to their research is the soluble protein CCL24, which plays a critical role in promoting both fibrosis and inflammation. By targeting this protein, Chemomab has developed CM-101, a monoclonal antibody that neutralizes CCL24's activity. This therapeutic candidate has shown promising safety and tolerability in both clinical and preclinical studies.

To date, Chemomab has reported positive outcomes from four clinical trials involving CM-101. These include a Phase 2 trial for primary sclerosing cholangitis (PSC), a Phase 2a trial for liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH), a Phase 1b study for metabolic dysfunction-associated fatty liver disease (MAFLD), and an investigator-initiated study focusing on severe lung injury. Additionally, the CM-101 program aimed at treating systemic sclerosis is ready to enter Phase 2 trials, with an open Investigational New Drug (IND) application in the United States.

Chemomab's commitment to addressing severe fibro-inflammatory conditions has shown significant potential to bring about new and effective treatments for diseases that currently lack sufficient therapeutic options. The company's progress in clinical trials underscores the potential impact of CM-101 in treating a variety of serious diseases characterized by fibrosis and inflammation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!